Development of Small Molecule RGS Inhibitors as a Mechanism to Modulate G-Protein Signaling.
dc.contributor.author | Blazer, Levi L. | en_US |
dc.date.accessioned | 2011-01-18T16:08:00Z | |
dc.date.available | 2012-02-21T18:47:02Z | en_US |
dc.date.issued | 2010 | en_US |
dc.date.submitted | en_US | |
dc.identifier.uri | https://hdl.handle.net/2027.42/78783 | |
dc.description.abstract | Regulator of G-protein Signaling (RGS) proteins are important regulatory molecules in the transduction of G-Protein Coupled Receptor (GPCR) signaling. They function by directly binding to G alpha subunits and accelerating GTP hydrolysis, thus potently inhibiting GPCR signaling. We and others have proposed that small molecule inhibitors of RGS proteins may provide a novel mechanism for therapeutic intervention in diseases stemming from deficiencies in GPCR signaling. This thesis details the identification and characterization of two novel classes of small molecule RGS inhibitors with unique properties. These compounds were identified from a series of high throughput screens performed by myself and others in our laboratory. The CCG-63802 class of molecules includes the first examples of reversible inhibitors of RGS4. These compounds can inhibit the in vitro binding and activity of several RGS proteins with IC50 values in the 3-100 micromolar range. They function by binding to RGS4 near a site thought to be important for allosteric regulation by endogenous acidic phospholipids. The second class of molecules, typified by CCG-50014, includes the most potent RGS4 inhibitors identified to date. This compound irreversibly inhibits RGS4 with nanomolar potency (IC50 30±6 nM) by covalently interacting with at least one cysteine on the RGS. In spite of the thiol dependence of these compounds, several members of this class can inhibit RGS binding and activity on G protein alpha subunits in living cells. Future work with these compounds is focused upon testing their activity in a variety of isolated organ and whole-animal studies. It is hoped that these compounds will provide a foundation for the development of new, more active RGS inhibitors with potential clinical and/or research utility. | en_US |
dc.format.extent | 3790768 bytes | |
dc.format.extent | 1373 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | en_US |
dc.subject | Small Molecule Protein-protein Interaction Inhibitor | en_US |
dc.subject | Regulator of G-protein Signaling | en_US |
dc.subject | G-protein | en_US |
dc.title | Development of Small Molecule RGS Inhibitors as a Mechanism to Modulate G-Protein Signaling. | en_US |
dc.type | Thesis | en_US |
dc.description.thesisdegreename | PhD | en_US |
dc.description.thesisdegreediscipline | Pharmacology | en_US |
dc.description.thesisdegreegrantor | University of Michigan, Horace H. Rackham School of Graduate Studies | en_US |
dc.contributor.committeemember | Neubig, Richard Robert | en_US |
dc.contributor.committeemember | Nikolovska-Coleska, Zaneta | en_US |
dc.contributor.committeemember | Tesmer, John | en_US |
dc.contributor.committeemember | Traynor, John R. | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/78783/1/llblazer_1.pdf | |
dc.owningcollname | Dissertations and Theses (Ph.D. and Master's) |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.